Profile data is unavailable for this security.
About the company
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.
- Revenue in GBP (TTM)18.55bn
- Net income in GBP1.71bn
- LocationAstraZeneca PLC- Legal Department, 2 Kingdom StreetLONDON W2 6BDUnited KingdomGBR
- Phone+44 20 7304 5000Fax+44 20 7604 8151
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|AZN:LSE since |
|Takeda Pharmaceutical Co Ltd-Respiratory Business||Deal completed||16 Dec 2015||16 Dec 2015Deal completed||16.49%||575.00m|
|Acerta Pharma BV||Deal completed||14 Dec 2015||14 Dec 2015Deal completed||18.13%||4.00bn|
|ZS Pharma Inc||Deal completed||06 Nov 2015||06 Nov 2015Deal completed||20.44%||2.69bn|
|Company||Revenue (TTM)||Net income (TTM)||Market cap||Employees||Market Cap /|
|Novo Nordisk A/S||110.34bn||36.06bn||597.33bn||42.27k||597.33bn42.27k|